Chronic Liver Disease and it’s Complications

Misbah  Arshad; Hina Asif; Akash John; Muhammad Omer Pasha

doi:10.54393/mjz.v1i1.7

Authors

Misbah Arshad Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
Hina Asif Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan
Akash John Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
Muhammad Omer Pasha Lahore General Hospital, Lahore, Pakistan

DOI:

https://doi.org/10.54393/mjz.v1i1.7

Abstract

Liver diseases progresses to more severe forms and thus are a major health problem. Cirrhosis and primitive liver cancer are significantly important in the west and are among the first 10 causes of death in adults. In all chronic liver diseases the final common pathway is liver cirrhosis, characterized by an accumulation of extracellular matrix rich in fibrillar collagens. Cirrhotic patients are at risk of developing many potential complications.One of the major complications of CLDs is Portal hypertension (PH),leads to the progression of portal vein-systemic collateral circulation that includes portal hypertensive gastropathy (PHG) and esophageal and gastric varices. Disabling and distressing manifestation of liver cirrhosis is tense ascites. In the presence of ascites alteration occurs in ventricular function. Cirrhosis may cause renal dysfunction, a common and potentially life threatening complication in hospitalized patients. Both acute kidney injury (AKI) and chronic kidney injury (CKD) are most common, often occurring simultaneously.

References

Moon AM, Singal AG & Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clinical Gastroenterology and Hepatology, 2020,18(12): 2650-2666. doi.org/10.1016/j.cgh.2019.07.060.

. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. Journal of Hepatology, 2019, 70(1): 172-193. doi.org/10.1016/j.jhep.2018.06.024.

. Woodhouse CA, Patel VC, Singanayagam A & Shawcross DL. the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Alimentary pharmacology & therapeutics, 2018,47(2): 192-202. doi.org/10.1111/apt.14397.

. Targher G, Lonardo A & Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nature reviews endocrinology, 2018,14(2): 99-114. doi:10.1038/nrendo.2017.173 .

. Farooq AA, Farooq A, Rashid M, Farooq JH, Umbreen S & Waseem R. Association of portal vein doppler parameters with chronic liver disease child pugh classes: A single center experience at Rawalpindi, Pakistan. Journal of Islamic International Medical College (JIIMC), 2019,14(1): 33-37.

Bhatti ABH & Dar FS. Living donor liver transplantation in Pakistan. Transplantation, 2017,101(7): 1507-1508. doi: 10.1097/TP.0000000000001737.

. WHO. www.who.int/vaccine_research/viral_cancers.2009

. Ng J & Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon, 2012,12(10 HCC): e7635. doi: 10.5812/hepatmon.7635

. Fan JG & Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. [Review]. J Hepatol, 2009,50(1): 204-210. doi: 10.1016/j.jhep.2008.10.010.

. Ooi PH, Hager A, Mazurak VC, Dajani K, Bhargava R, Gilmour SM & Mager DR. Sarcopenia in chronic liver disease: impact on outcomes. Liver Transplantation, 2019,25(9): 1422-1438. doi.org/10.1002/lt.25591.

. Eslam M, Sarin SK, Wong VWS, Fan JG, Kawaguchi T, Ahn SH, ... & George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology International, 2020. 14(6): 889-919. doi.org/10.1007/s12072-020-10094-2.

. Dharmalingam M & Yamasandhi PG. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism, 2018,22(3): 421. dx.doi.org/10.4103%2Fijem.IJEM_585_17.

. Huang X, Liu X & Yu Y. Depression and chronic liver diseases: are there shared underlying mechanisms?. Frontiers in Molecular Neuroscience, 2017,10: 134. doi.org/10.3389/fnmol.2017.00134.

. Sarin SK, Choudhury A, Lau GK, Zheng MH, Ji D, Abd-Elsalam S, ... & Omata M. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatology International, 2020,14(5), 690-700. doi.org/10.1007/s12072-020-10072-8.

Dang K, Hirode G, Singal AK, Sundaram V & Wong RJ. Alcoholic liver disease epidemiology in the United States: a retrospective analysis of 3 US databases. Official Journal of the American College of Gastroenterology, ACG, 2020,115(1): 96-104. doi: 10.14309/ajg.0000000000000380.

. Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, ... & Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. The Lancet Infectious Diseases, 2017,17(10): 1062-1068. doi.org/10.1016/S1473-3099(17)30496-6.

. Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y, ... & Nishiguchi S. Transition in the etiology of liver cirrhosis in Japan: a nationwide survey. Journal of Gastroenterology, 2020,55(3): 353-362. doi.org/10.1007/s00535-019-01645-y.

. Palmer DH & Johnson PJ. Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma. Cancer and Metastasis Reviews, 2015, 34(3): 497-509. doi 10.1007/s10555-015-9580-2.

. Rahimi RS & Rockey DC. Complications of cirrhosis. Current Opinion in Gastroenterology, 2012, 28(3): 223-229. doi: 10.1097/MOG.0b013e328351d003.

. Cavanaugh J, Niewoehner CB & Nuttall FQ. Gynecomastia and cirrhosis of the liver. Archives of Internal Medicine, 1990, 150(3): 563-565. doi:10.1001/archinte.1990.00390150061012.

. Eiji Kakazu YK, Tooru S. The Relationship between Renal Dysfunction and Abnormalities of the Immune System in Patients with Decompensated Cirrhosis. ISRN Gastroenterol, 2012, (2012: 123826.). doi: 10.5402/2012/123826

Starr SP & Raines D. Cirrhosis: diagnosis, management, and prevention. American Family Physician, 2011, 84(12): 1353-1359.

. El-Ashry NEDM, Salem M, Mogawer S. Large volume abdominal paracentesis effect on some humoral factors and cardiac performance in patients with liver cirrhosis and tense ascities. Journal of the Egyptian Society of Parasitology,2007, 37(2): 571.

Bleibel W & Al-Osaimi A. Hepatic encephalopathy. Saudi Journal of Gastroenterology, 2012,18(5): 301.

. Asim MS, Kar MPP. Aetiological and molecular profile of hepatocellular cancer from India. Int J Cancer. 2012, doi: 10.1002/ijc.27993.

. Lee JH, Jang JW, Cho CH, Kim JY, Han ET, Yun SG, Lim CS. False-positive results for rapid diagnostic tests for malaria in patients with rheumatoid factor. J Clin Microbiol. 2014,52(10):3784-7. doi: 10.1128/JCM.01797-14.

. Utzeri E & Usai P. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease. World J Gastroenterology, 2017,23(22): 3954. dx.doi.org/10.3748%2Fwjg.v23.i22.3954.

. Kim RG, Loomba R, Prokop LJ & Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clinical Gastroenterology and Hepatology, 2017,15(10): 1521-1530. doi.org/10.1016/j.cgh.2017.04.039.

. Stravitz RT, Ellerbe C, Durkalski V, Schilsky M, Fontana RJ, Peterseim C, ... & Acute Liver Failure Study Group. Bleeding complications in acute liver failure. Hepatology, 2018,67(5): 1931-1942. doi.org/10.1002/hep.29694.

. Qamar A, Vaduganathan M, Greenberger NJ & Giugliano RP. Oral anticoagulation in patients with liver disease. Journal of the American College of Cardiology, 2018,71(19): 2162-2175.

Hernaez R, Liu Y, Kramer JR, Rana A, El-Serag HB & Kanwal F. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. Journal of Hepatology, 2020,73(6): 1425-1433. doi.org/10.1016/j.jhep.2020.06.005.

Guo X, Wu F, Guo W, Zhang J, Yang Y, Lu Y, ... & Liao M. Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure. Journal of International Medical Research, 2020,48(6): 0300060520932053.doi.org/10.1177%2F0300060520932053.

Francoz C, Durand F, Kahn JA, Genyk YS & Nadim MK. Hepatorenal syndrome. Clinical Journal of the American Society of Nephrology, 2019,14(5): 774-781. doi.org/10.2215/CJN.12451018.

Piano S, Tonon M & Angeli P. Management of ascites and hepatorenal syndrome. Hepatology International, 2018,12(1): 122-134. doi.org/10.1007/s12072-017-9815-0.